RxDoctor Payments Data

Yan Yan, MD

Allergy & Immunology · Burlingame, CANPI 1154663771

Payments from drug & device makers

$3,630in general payments, 2019–2025

Across 120 payments — averaging $30.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$657
  • Sanofi$525
  • AstraZeneca$438
  • Aimmune Therapeutics, Inc.$350
  • Optinose US, Inc.$270
  • Regeneron Healthcare Solutions, Inc.$167
  • plus $1K from 18 others

What the payments were for

  • Speaking & faculty fees$35010%
  • Food & beverage$3,14387%
  • Education$1374%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,630 in reported general payments places this provider in the 50th percentile of 426 allergy & immunology providers in California.

See all allergy & immunology providers in California

Medicare billing

Part B allowed, 2024
$27,257
Medicare patients
39
Services billed
1,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucalaMepolizumab38$136,295
Dupixent SyringeDupilumab38$131,141
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$33,339
Breo ElliptaFluticasone/Vilanterol28$13,801
XhanceFluticasone Propionate11$7,111
Azelastine Hcl142$2,800
Levocetirizine Dihydrochloride160$2,456
Tacrolimus19$1,992
Betamethasone Dipropionate38$1,101
Fluocinonide28$929
Albuterol Sulfate HfaAlbuterol Sulfate19$796
Ammonium Lactate68$784
Desloratadine18$503
Montelukast Sodium61$375
Ipratropium Bromide13$352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala, Trelegy Ellipta, Breo Ellipta$657$183,435114 claims
Optinose US, Inc.Xhance$270$7,11111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 426 allergy & immunology providers in California.

Other allergy & immunology in Burlingame

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →